

## PUBLICATIONS

McClanahan F, Hielscher T, Rieger M, Hensel M, Bentz M, Schmidt-Wolf I, Käbisch A, Salwender H, Dürk H, Staiger H, Mandel T, Neben K, Hillengass J, **Leo E**, Krämer A, Ho AD, Witzens-Harig M.

**Final results of a randomized trial comparing 1, 3, or 6 infusions of Rituximab plus 6 cycles CHOP provide valuable preliminary data towards a more cost-effective and safer treatment of advanced follicular lymphoma.**

*Am J Hematol.* 2012 Oct;87(10):E68-71

Stühmer T, Arts J, Chatterjee M, Borawski J, Wolff A, King P, Einsele H, **Leo E**, Bargou RC.

**Preclinical anti-myeloma activity of the novel HDAC-inhibitor JNJ-26481585.**

*Br J Haematol* 2010;149(4):529-36

Kornacker M, Kornacker B, Schmitt C, **Leo E**, Ho AD, Hensel M.

**Commercial LightCycler-based quantitative real-time PCR compared to nested PCR for monitoring of Bcl-2/IgH rearrangement in patients with follicular lymphoma.**

*Ann Hematol* 2009;88(1):43-50.

Bargou R, **Leo E** (shared first authorship), Zugmaier G, Klinger M, Goebeler M, Knop S, Noppeney R, Viardot A, Hess G, Schuler M, Einsele H, Brandl C, Wolf A, Kirchinger P, Klappers P, Schmidt M, Riethmüller G, Reinhardt C, Baeuerle PA, Kufer P.

**Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.**

*Science* 2008; 321(5891):974-7.

Oberneder R, Weckermann D, Ebner B, Quadt, Kirchinger P, Raum T, Locher M, Prang N, Baeuerle PA, **Leo E**

**A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients**

*Eur J Cancer* 2006; 42(15):2530-8

Schmitt C, Grundt A, Buchholtz C, Scheuer L, Benner A, Hensel M, Ho AD, [Leo E](#)

**One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?**

*Leukemia Res* 2006; 30(12):1563-8

Schmitt C, Balogh B, Grundt A, Buchholtz C, Leo A, Benner A, Hensel M; Meuer S, Ho AD, [Leo E](#)

**The Bcl-2/IgH rearrangement in a population of 204 healthy individuals: Occurrence, age and gender distribution, break points and detection method validity**

*Leukemia Res* 2006 Jun;30(6):745-50.

Breuhahn K, Baeuerle PA, Peters M, Prang N, Töx U, Koehne-Volland R, Dries V, Schirmacher P, [Leo E](#)

**Expression of epithelial cellular adhesion molecule (Ep-CAM) in chronic (neco-)inflammatory liver diseases and hepatocellular carcinoma.**

*Hepatology Research* 2006; 34:50-6.

Schlereth B, Quadt C, Dreier T, Kufer P, Lorenczewski G, Prang N, Brandl C, Lippold S, Cobb K, Brasky K, [Leo E](#), Bargou R, Murthy K, Baeuerle PA

**T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.**

*Cancer Immunol Immunother* 2006; May;55(5):503-14.

[Leo E](#), Scheuer L, Schmidt-Wolf IGH, Kerowgan M, Schmitt C, Leo A, Baumbach T, Kraemer A, Mey U, Benner A, Parwaresch R, Ho AD

**Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.**

*Eur J Hematol* 2004; 73:251-7

[Leo E](#), Krämer A, Krasniqi F, Hochhaus A, Hehlmann R, Ho AD

**Gangrene of the toes in a patient with chronic myelogenous leukemia after long-term hydroxyurea therapy.**

*Ann Hematol* 2002; Aug;81(8):467-9.

Kornacker M, Kraemer A, **Leo E**, Ho AD

**Occurrence of sarcoidosis subsequent to chemotherapy for non-Hodgkin's lymphoma: report of two cases.**

*Ann Hematol* 2002; Feb;81(2):103-5.

**Leo E**, Deveraux Q, Buchholtz C, Welsh K, Matsuzawa S, Stennicke H, Salvesen GS, Reed JC

**TRAF1 is cleaved by caspases during TNF- and FAS-mediated apoptosis.**

*J Biol Chem* 2001; Mar 16;276(11):8087-93.

Ni CZ, Welsh K, **Leo E**, Chiou CK, Wu H, Reed JC, Ely KE

**Crystal structure of the signaling protein TRAF3 bound to a fragment of CD40.**

*Proc Natl Acad Sci* 2000; 97(19):10395-9

Zapata JM, Matsuzawa S, Godzik A, **Leo E**, Wasserman SA, Reed JC

**The drosophila tumor necrosis factor receptor-associated factor-1 (D-TRAF1) interacts with pelle and regulates NF- $\kappa$ B activity.**

*J Biol Chem* 2000; 275(16):12102-7

**Leo E**, Zapata JM, Reed JC

**CD40-Mediated activation of Ig-C1-and Ig-C-germline promoters involves multiple TRAF-family proteins.**

*Eur J Immunol* 1999; 29(12):3908-13

Ye X, Mehlen P, Rabizadeh S, VanArsdale T, Zhang H, Shin H, Wang JJ, **Leo E**, Zapata J, Hauser CA, Reed JC, Bredesen DE

**TRAF family proteins interact with the common neurotrophin receptor and modulate apoptosis induction.**

*J Biol Chem* 1999; 274(42):30202-8

Deveraux QL, **Leo E**, Stennicke HR, Welsh K, Salvesen GS, Reed JC

**Cleavage of human inhibitor of apoptosis protein XIAP results in fragments with distinct specificities for caspases.**

*EMBO J* 1999; 18(19):5242-51

**Leo E**, Welsh K, Matsuzawa S, Zapata JM, Kitada S, Mitchell RS, Ely KR, Reed JC

**Differential requirements for tumor necrosis factor receptor-associated factor family proteins in CD40-mediated induction of NF-kappaB and JunN-terminal kinase activation.**

*J Biol Chem* 1999; 274(32):22414-22

**Leo E**, Schlegel PG, Lindemann A

**Chemotherapeutic induction of long-term remission in metastatic medulloblastoma.**

*J Neurooncology* 1997; 32(2):149-54

**Leo E**, Kropff M, Lindemann A, Steinfurth G, Esselborn H, Rossner R, Adler CP, Bocking A

**DNA aneuploidy, increased proliferation and nuclear area of plasma cells in monoclonal gammopathy of undetermined significance and multiple myeloma.**

*Anal Quant Cyt Histol* 1995; 17(2):113-20

Kropff M, **Leo E**, Steinfurth G, Adler CP, Bocking A.

**DNA-cytometry and clinical staging systems in prognosis of multiple myeloma.**

*Anticancer Res* 1994; 14: 2183-8

## ABSTRACTS/TALKS

Levis M, Perl AE, Dombret H, Döhner H, Steffen B, Rousselot P, Martinelli G, Estey EH, Burnett AK, Gammon G, Trone D, **Leo E**, Cortes JE

**Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients with FLT3-ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia After Second-Line Chemotherapy or Hematopoietic Stem Cell Transplantation**

*American Society of Hematology 2011; Annual Meeting; #673*

Cortes JE, Perl AE, Dombret H, Kayser S, Steffen B, Rousselot P, Martinelli G, Estey EH, Burnett AK, Gammon G, Trone D, **Leo E**, Levis M]

**Final Results of a Phase 2 Open-Label, Monotherapy Efficacy and Safety Study of Quizartinib (AC220) in Patients  $\geq$  60 Years of Age with FLT3 ITD Positive or Negative Relapsed/Refractory Acute Myeloid Leukemia.**

*American Society of Hematology 2011; Annual Meeting; #48*

Cortes JE, Perl, AE, Smith CC, Kovacsovics T, Dombret H, Dohner H, Steffen B, Pigneux A, Rousselot P, **Leo E**, Gammon G, Levis M]

**A Phase II Open-Label, AC220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-ITD Positive Acute Myeloid Leukemia : Updated Interim Results**

*American Society of Hematology 2011; Annual Meeting; #614*

Cortes JE, Perl, AE, Smith CC, Kovacsovics T, Dombret H, Dohner H, Steffen B, Pigneux A, Rousselot P, **Leo E**, Corringham B, Trikha M, Levis M]

**A phase II open-label, AC220 monotherapy efficacy (ACE) study in patients with acute myeloid leukemia (AML) with FLT3-ITD activating mutations: Interim Results**

*European Hematology Association 2011, Annual Meeting, London. #1014*

## **Leo E**

**Are There Ways to Truly Accelerate Early Drug Development?**

**“Latest Advances on Anticancer Drugs in Clinical Development”;**

*5th European Spring Oncology Conference; Marbella, Málaga, Spain. June 26, 2008*

Taberbero J, Schöffsky P, Dirix L, Capdevila J, Dumez H, Kraljevic S, Bol K, Winkler H, de Bie L, Rooney B, Arts J, **Leo E**

**First-in-human study of the first-in-class Hdm2 inhibitor JNJ-26854165.**

*Annual EORTC-NCI-AACR Conference on "Molecular targets and cancer therapeutics" 2008, Geneva.*

Stuehmer T, Arts J, King P, Borawski J, Page M, **Leo E**, Bargou RC

**Preclinical evaluation of the novel HDAC-inhibitor JNJ-26481585 in multiple myeloma reveals strong anti-tumor activity**

*American Association for Cancer Research 2008; Annual Meeting, #738*

Arts J, Page M, Valckx A, Blattner C, Kulikov R, Floren W, van Nuffel L, Janssen L, King P, Masure S, Smans K, Verhasselt P, Goehlmann H, Ligny Y, Lardeau D, Csoka I, Andries L, Brehmer D, Freyne E, **Leo E**, Janicot M, Meyer C, Lacrampe J, Schoentjes B

**JNJ-26854165 - a novel hdm2 antagonist in clinical development showing broad-spectrum preclinical antitumor activity against solid malignancies.**

*American Association for Cancer Research 2008; Annual Meeting, # 1592*

Stuehmer T, Arts J, King P, Page M, Bommert K, **Leo E**, Bargou RC

**A first-in-class HDM2-inhibitor (JNJ-26854165) in phase I development shows potent activity against multiple myeloma (MM) cells in vitro and ex vivo.**

*J Clin Oncol 2008; Suppl 26; May 20; #14694*

Arts J, Page M, Valckx A, Blattner C, Kulikov R, Floren W, van Nuffel L, Janssen L, King P, Masure S, Smans K, Verhasselt P, Goehlmann H, Ligny Y, Lardeau D, Csoka I, Andries L, Brehmer D, Freyne E, **Leo E**, Janicot M, Meyer C, Lacrampe J, Schoentjes B.

**Preclinical anti-tumor studies with JNJ-26854165 – A novel class of Hdm2 antagonist**

## IN CLINICAL DEVELOPMENT

NCI-EORTC-AACR Conference on Targeted Therapies 2007, Washington D.C.  
Bommert K, Knop S, Arts J, King P, Page M, **Leo E**, Bargou R

**Novel 2<sup>nd</sup> generation histone deacetylase inhibitor (JNJ-26481585) exhibits potent antitumor activity against chronic lymphocytic leukemia cells in vitro and ex vivo.**

*American Society of Hematology 2007; Annual Meeting*

Bargou R, Kufer P, Goebeler M, Knop S, Einsele H, Noppeney R, Viardot A, Hess G, Riethmueller G, Reitsma D, **Leo E**, Reinhardt C, Zugmaier G

**The anti-CD19 bispecific T-cell engager (BiTE) MT103 (MEDI-538), induces dose-dependent objective complete and partial responses in relapsed non-Hodgkin's lymphoma (NHL): update from the ongoing phase I study MT103-104.**

*American Society of Hematology 2007; Annual Meeting*

Arts J, Mariën A, King P, Floren W, Beliën W, Janssen L, Pilatte I, Roux B, Decrane L, Gilissen R, Andries L, Du Jardin M, Janicot M, Hellemans P, **Leo E**, van Hijfte L, Freyne E, van Emelen K, Page M, Angibaud P

**JNJ-26481585: a novel "second-generation" oral pan-Histone Deacetylase (HDAC) inhibitor showing broad-spectrum preclinical antitumoral activity against solid tumors and hematological malignancies**

*Discovery on Target conference 2007; Boston*

Bargou R, Noppeney R, Schuler M, Hess G, Gerecke C, Zettl F, Birkmann J, Viardot A, Kirchinger P, Baeuerle P, Reinhardt C, Klinger M, Libicher M, Goebeler M, Einsele H, Kufer P, Zugmaier G, **Leo E**

**The bi-specific T-cell enhancer (BiTE) MT103 (MEDI-538) induces clinical responses in heavily pre-treated NHL patients: Update from the ongoing phase I study MT103-104.**

*American Society of Hematology 2006; Annual Meeting, # 2725*

Klinger M, Kufer P, Kirchinger P, Lutterbüse R, **Leo E**, Reinhardt C, Baeuerle P, Bargou R

**T cell responses during long-term continuous infusion of MT103 (MEDI-538; Anti-CD19 BiTE) in patients with relapsed B-NHL.**

*American Society of Hematology 2006; Annual Meeting, # 693*

Bargou R, Kufer P, Kirchinger P, Noppeney R, Schuler M, Viardot A, Weigang-Köhler K, Zettl F, Libicher M, Riethmüller G, Lutterbüse R, **Leo E**, Klinger M,

**Reinhardt C, Bäuerle P: MT103 (Anti-CD19 x Anti-CD3 BiTE) induces B cell depletion, clearance of bone marrow infiltration and clinical responses in heavily pretreated NHL patients: First data from dose-escalation study MT103-104**

*European Hematology Association 2006; Annual Meeting, # 0189 & #0503*

Hensel M, Scheuer L, Salwender H, Finke J, Buerkle D, Duerk H, Kaebisch A, Naumann R, Staiger HJ, Schmidt-Wolf I, Kornacker M, **Leo E**, Fischer J, Ho AD

**How Much Rituximab Do We Need: A Multicenter, Randomized Trial Comparing 1, 3 or 6 Infusions of Rituximab Added to 6 Cycles of CHOP Chemotherapy in Untreated Patients with Advanced Follicular Non-Hodgkins Lymphoma (HD2000-Trial).**

*Blood (ASH Annual Meeting Abstracts), 2004; 104: 4584.*

Heidenreich A, Ohlmann C, **Leo E**, Bäuerle PA, Da Silva A, Roessler S, Barth P, Moll R

**Epithelial cell adhesion molecule (Ep-CAM) – a potential therapeutic target in prostate cancer (PCA)**

*Deutsche Gesellschaft für Urologie; Jahrestagung*

Balogh B, **Leo E**, Grundt A, Buchholtz C, Ho AD, Schmitt C

**Monitoring Minimal Residual Disease (MRD): Comparing two frequently used techniques regarding feasibility, sensitivity/specificity and economics for detection of the bcl-2/IgH rearrangement**

*ESEC-ESMO Meeting 2005; Budapest*

Hensel M, Scheuer L, Salwender H, Finke J, Bürkle D, Dürk HA, Käbisch A, Naumann R, Staiger HJ, Kornacker M, **Leo E**, Fischer J, Ho AD

**Wieviel Rituximab ist erforderlich zur Erzielung hoher molekularer und klinischer Remissionsraten: Eine multizentrische, randomisierte Studie zum Vergleich von 1, 3 oder 6 Rituximab-Infusionen in Kombination mit 6 Zyklen CHOP bei unbehandelten Patienten mit fortgeschrittenem follikulärem Non-Hodgkin Lymphom.**

*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2004; Jahreskongress*



Balogh B, Buchholtz C, Richter P, Ho AD, **Leo E**

**Frequency of t(14;18) translocation in healthy individuals**

*Proceedings of the American Society of Clinical Oncology 2003; 20, 292a*

**Leo E**, Scheuer L, Kraemer A, Kerowgan M, Leo A, Ho AD

**Unexpected hematotoxicity associated with a combination of rituximab, fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma.**

*American Society of Hematology 2001; Annual Meeting, # 4745*

Kraemer A, Zoz M, Krasniqi F, Goerner M, **Leo E**, Ho AD

**Treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of a taxane, cyclophosphamide and rituximab.**

*American Society of Hematology 2001; Annual Meeting, # 569*

**Leo E**, Bertz H, Koehler G, Colgan JP, Kurtin J, Finke J

**Treatment of aggressive, recurrent, subcutaneous panniculitis-like T-cell non-Hodgkin's lymphoma (SPTCL) with high-dose chemotherapy followed by allogeneic peripheral blood stem cell transplantation.**

*American Society of Hematology 2001, Annual Meeting, # 5287*

Probst S, **Leo E**, Kraemer A, Egerer G, Haas R, Ho AD

**Autologous transplantation as primary treatment strategy vs. at relapse for follicular lymphoma upon long term follow-up.**

*American Society of Hematology 2001, Annual Meeting, # 5376*

Probst S, **Leo E**, Krämer A, Abdallah A, Egerer G, Körbling M, Haas R, Ho AD

**High-dose therapy with autologous stem cell transplantation for patients with follicular low grade non-Hodgkin's lymphoma - an analysis of late effects of transplantation**

*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2001; Jahreskongress*

Probst S, **Leo E**, Kraemer A, Egerer G, Haas R, Ho AD

**Primary treatment strategy versus at relapse for follicular lymphoma upon long term follow-up.**

*American Society of Hematology 2000; Annual Meeting*

Zoz M, Krämer A, Krasniqi F, Görner M, **Leo E**, Ho AD

**Taxane, cyclophosphamide plus rituximab in patients with relapsed and refractory aggressive non-Hodgkin's lymphoma. (Onkologie 2001)**

*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2001; Jahreskongress*

Probst S, **Leo E**, Krämer A, Abdallah A, Egerer G, Körbling M, Haas R, Ho AD

**Long-term outcome and adverse events in patients with low-grade follicular lymphoma after autologous transplantation.**

*Proceedings of the American Society of Clinical Oncology 2001; 20 292a*

**Leo E**, Bertz H, Köhler G, Finke J

**Successful treatment of aggressive, recurrent subcutaneous panniculitis-like T-cell non-Hodgkin's lymphoma (SPTLC) with high-dose chemotherapy followed by allogeneic peripheral blood stem cell transplantation.**

*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2001; Jahreskongress+*

**Leo E**, Ciamango O, Krasniqi F, Krämer A, Ho AD

**Gangrene of the toes during hydroxy-urea therapy in chronic myelogenous leukemia - a case report.**

*Deutsche Gesellschaft für Hämatologie und internistische Onkologie 2000; Jahreskongress*

**Leo E**, Loeber T, Deveraux Q, Welsh K, Stennicke H, Salvesen GS, Reed JC

**A distinct region of the Human Inhibitor of Apoptosis (IAP) protein cIAP1 interacts with caspases 3, -7 and -9.**

*American Society of Hematology 2000; Annual Meeting*

**Leo E**, Deveraux Q, Matsuzawa S, Welsh K, Reed JC

**TRAF1 is cleaved by caspases during TNF- and Fas-mediated apoptosis**

*American Association for Cancer Research 2000; Annual Meeting*

**Leo E**, Deveraux Q, Matsuzawa S, Welsh K, Reed JC

**TRAF1 is cleaved by caspases during TNF- and Fas-mediated apoptosis**

*American Association for Cancer Research 2000; Annual Meeting*

**Leo E**, Zapata JM

**Reed JC CD40-Mediated activation of Ig-Cgamma1-and Ig-Cepsilon-germline promoters involves multiple TRAF-family proteins.**

*American Society of Hematology 1999; Annual Meeting*

**Leo E**, Welsh K, Matsuzawa S and Reed, JC

**TRAF2 and TRAF3 are non-essential for CD40 activation of NF-kB.**

*American Association for Cancer Research 1999; Annual Meeting*

**Leo E**, Kropff M, Lindemann A, Adler C, Oster W, Boecking A

**DNA-Aneuploidy, increased proliferation and nuclear area of plasma cells as early markers of prospective malignancy in Monoclonal Gammopathy of Undetermined Significance.**

*American Association for Cancer Research 1992; Annual Meeting*

Kropff M, **Leo E**, Steinfurth G, Adler CP, Böcking A

**DNA-zytometrischer Nachweis von Aneuploidie, erhöhter Proliferation und Kernfläche als frühe Marker prospektiver Malignität bei monoklonaler Gammopathie unklarer Signifikanz (MGUS)**

*Verh Dtsch Ges Path 1991; 75, 480*